- Global Pharma News & Resources


DGAP-News: Evotec SE / Key word(s): 9 Month figures

12.11.2019 / 07:01
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, 12 November 2019:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the first nine months ended 30 September 2019.


  • Group revenues: 16% increase to EUR 321.4 m (9M 2018: EUR 278.1 m)
  • Adjusted Group EBITDA up 36% to EUR 93.2 m (9M 2018: EUR 68.7 m)
  • Unpartnered R&D expenses of EUR 25.7 m (9M 2018: EUR 16.0 m)
  • Strong liquidity position of EUR 282.6 m (31 December 2018: EUR 149.5 m)


  • Multiple new alliances in EVT Innovate and EVT Execute
  • Just - Evotec Biologics off to a very good start
  • Achievement of multiple important milestones (e.g. Bayer, Boehringer Ingelheim, Celgene, Indivumed)
  • Co-owned pipeline projects progressing very well, e.g. with positive Phase II POC results in chronic cough with Bayer
  • Extension of iPSC-based neurodegeneration partnership with Celgene into 2023; triggering additional $ 30 m payment
  • Joint venture created with Vifor Pharma focused on novel nephrology therapeutics (after period-end)
  • Expansion of BRIDGE roll-out with new BRIDGEs LAB10x and LAB555 (after period-end)
  • Continued company formations and equity participation e.g. in Aeovian, Eternygen, Facio, Immunitas; and spin-off formation Breakpoint Therapeutics GmbH focused on DNA damage response
  • Building a leading position in anti-infectives discovery and development (e.g. alliances with GARDP, GNA Now, Helmholtz, and the Bill & Melinda Gates Foundation)

Full-year 2019 guidance for revenue and unpartnered R&D costs confirmed; EBITDA
guidance increased to approximately 15% (previously: >10%)

In the first nine months of 2019, Evotec's Group revenues continued their strong performance and increased by 16% to EUR 321.4 m (9M 2018: EUR 278.1 m). This positive development is mainly due to the very strong performance in the base business across all business lines, solid milestone payments, and first revenue contributions by Just - Evotec Biologics (EUR 10.4 m). Revenues from milestones upfronts and licences, which can vary significantly from quarter to quarter, decreased to EUR 22.3 m in comparison to the previous year (9M 2018: EUR 27.2 m) and included, amongst others, payments from Bayer, Boehringer Ingelheim, and Celgene.

The gross margin in the first nine months of 2019 amounted to 30.7% (9M 2018: 30.1%). This increase in margin compared to 2018 is based on very good capacity utilisation and favourable FX.

In the first nine months of 2019, Evotec focused its unpartnered R&D expenses of EUR 25.7 m primarily on initiatives in the fields of metabolic diseases, oncology, and platform projects. Its partnered R&D expenses of EUR 15.6 m on its infectious disease portfolio were shown under R&D while the expenses fully reimbursed by its partner Sanofi were recognised under other operating income. This split into unpartnered and partnered R&D expenses had not been applied in the first nine months of 2018, where total R&D expenses of EUR 16.0 m were recorded compared to total EUR 41.3 m in the reporting period.

The Group's selling, general and administrative ("SG&A") expenses increased by 13% to EUR 46.2 m (9M 2018: EUR 40.8 m) in the first nine months of 2019. This increase is mainly due to overall company growth including staff increases, upgrading of systems, consultancy fees, plus expenses from acquired companies, equity and financing transactions.

Impairments of intangible assets and goodwill of EUR 11.9 m were recorded (9M 2018: impairment of intangible assets of EUR 4.2 m). This one-off impairment was mainly due to the termination of the SGM-1019 agreement by our partner Second Genome, the programme was fully impaired (EUR 10.3 m). This impairment of intangible assets in addition triggered a goodwill impairment of EUR 1.6 m of the cash-generating unit Evotec (US) Innovate. All rights of the underlying asset were returned to Evotec.

The strong increase in the adjusted Group EBITDA to EUR 93.2 m (9M 2018: EUR 68.7 m), resulted mainly from the very strong performance in the base business, solid milestones and licence contributions, a positive EBITDA contribution by Just - Evotec Biologics and effects from the first-time application of the new accounting standard IFRS 16 (+EUR 10.1 m).

In the first nine months of 2019, Evotec's operating result was EUR 46.4 m (9M 2018: EUR 59.5 m). A year on year comparison is not meaningful, as 2018 was significantly positively affected by a one-off impact from the bargain purchase ID Lyon in 2018 (EUR 15.4 m). The Company's net result for the first nine months of 2019 amounted to EUR 29.7 m (9M 2018: EUR 52.3 m) and also cannot be compared like for like as it was affected by the one-off effect of the impairments on intangible assets and goodwill.

Evotec ended the third quarter of 2019 with a strong liquidity position of EUR 282.6 m (31 December 2018: EUR 149.5 m), which was composed of cash and cash equivalents (EUR 249.6 m) and investments (EUR 33.0 m). In the first nine months of 2019, liquidity was primarily affected by the completion of the repayment of the remainder of the EUR 140 m debt bridge facility drawn down in context of the acquisition of Aptuit in August 2017 as well as the repayment of flexible bank loan agreements, the successful issue of a promissory note (Schuldschein) worth EUR 250 m, gross, at very attractive interest rates of below 1.5%, as well as the draw-down of another tranche of the European Investment Bank R&D loan and the acquisition of Just - Evotec Biologics.

Overall, the EVT Execute segment continued its strong progress in existing alliances and signed new or extended established partnerships. The strong performance was highlighted through the signing of a strategic multi-year drug discovery collaboration across multiple therapeutic areas with Takeda. Evotec will use its leading integrated drug discovery platform to deliver clinical candidates for Takeda to pursue into clinical development. Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $ 170 m per programme as well as tiered royalties on future sales.

The Just - Evotec Biologics integration into the Evotec Group is fully on track. In the first three months since the acquisition, Just - Evotec Biologics signed new agreements e.g. with Teva and Biocon Biologics.

EVT Innovate continued to deliver strong progress within its collaborations, signed important new contracts and extensions plus achieved major advances in Evotec's co-owned pipeline. Bayer achieved positive Phase II POC results with its P2X3 antagonist in chronic cough showing good efficacy and safety.

Evotec's academic BRIDGE portfolio has been expanded through LAB555 (after period-end), the first BRIDGE built in Israel. The partnership aims to expedite drug discovery and development by providing efficient translation of early stage Hebrew University research.

Evotec continues to invest in promising companies with operational synergies. Evotec was participating in Aeovian's series A financing after successfully delivering Aeovian's first candidate drug, and formed its second spin-off Breakpoint Therapeutics, a virtual company focusing on the development of Evotec's DNA damage response portfolio. Furthermore, Evotec invested in the NewCo Immunitas Therapeutics, a Boston-based monoclonal antibody company.

Furthermore, Evotec expanded its position, being at the forefront of women's health and anti-infective drug discovery. Evotec entered an alliance with Celmatix, a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women's reproductive health, including polycystic ovary syndrome, endometriosis, and infertility.

In the field of anti-infectives, Evotec closed additional collaborations, e.g. kicking off "GNA Now", a new initiative for the development of novel antibacterial agents. The increasing recognition of antibiotic resistance as growing threat to public healthcare systems enabled Evotec to receive grants for projects to further accelerate drug discovery efforts in this area of high medical need.

After period-end, Evotec and Vifor Pharma launched a joint venture focused on the discovery and development of novel nephrology therapeutics. Both companies will hold a 50% share, with Vifor Pharma benefiting from access to an external R&D capability for the development of a Nephrology pipeline, while Evotec will gain access to a commercial partner for assets developed through the Joint Venture. The initial funding of EUR 25 m for pre-clinical development will be covered by Vifor Pharma, while Evotec contributes its PanHunter bioinformatics platform and high-quality data sets from thousands of human kidney disease patients to the Joint Venture.

Full-year 2019 guidance for revenue and unpartnered R&D costs confirmed; EBITDA
guidance increased to approximately 15% (previously: >10%)

  Guidance 2019 Actual 2018
Group revenues from contracts with customers without revenues from recharges Approx. 15% growth1) EUR 364.0 m2)
Unpartnered R&D expenses Approx. EUR 30-40 m EUR 22.9 m
Adjusted Group EBITDA3) Improve by approx. 15% compared to 2018 EUR 92.0 m4)

1) Based on current/updated FX rates
2) 2018 total revenues excluding revenues from recharges according to IFRS 15
3) EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. Adjusted EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result
4)2018 total adjusted Group EBITDA excluding EUR 3.5 m one-off effects in 2018

Webcast/Conference Call
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Conference call details
Date: Tuesday, 12 November 2019
Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 25877742#

A simultaneous slide presentation for participants dialling in via phone is available at

Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.

The access code is 315534326#. The on-demand version of the webcast will be available on our website:


The 2018 and 2019 results are not fully comparable. The difference stems from the acquisition of Evotec ID (Lyon) SAS, effective 01 July 2018. The results from Evotec ID (Lyon) SAS are only included from 01 July 2018 onwards. Furthermore, Just - Evotec Biologics (former Just Biotherapeutics) was acquired effective 02 July 2019. The results from Just - Evotec Biologics are included from 02 July 2019 onwards.

The accounting policies used to prepare this interim information are the same as those used to prepare the audited consolidated financial statements for the year ended 31 December 2018, except for the adoption of IFRS 16 which is applied at Evotec as of 01 January 2019.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including, Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to and follow us on Twitter @Evotec.

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

First nine months 2019 results

Key figures of consolidated interim income statement
Evotec SE and subsidiaries

In TEUR except share data and per share data

  January to September
July to September Change
  2019 20181) in % 2019 20181) in %
Revenues from contracts with customers 321,362 278,088 15.6 114,274 99,213 15.2
Gross margin in % 30.7 30.1   30.6 33.7  
Research and development expenses (41,285) (20,943) 97.1 (11,997) (10,928) 9.8
Selling, general and administrative expenses (46,230) (40,753) 13.4 (16,325) (13,636) 19.7
Impairment of intangible assets and goodwill (11,919) (4,167) >100.0 - - -
Other operating income (expenses), net 47,050 26,289 79.0 15,702 13,592 15.5
Operating result 46,425 59,518 (22.0) 22,389 37,828 (40.8)
Adjusted Group EBITDA2)


35.7 35.006 30,118 16.2
Net income 29,709 52,275 (43.2) 12,365 34,408 (64.1)
Weighted average shares outstanding 149,496,540 147,299,051 1.5 149,785,303 147,311,368 1.7
Net income (loss) per share (basic and diluted) 0.20 0.35 42.9 0.08 0.23 (65.2)

1) Including reclasses of recharges according to IFRS 15
2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible
and tangible assets as well as the total non-operating result

Segment information:

First nine months 2019


  EVT Execute EVT Innovate Intersegment eliminations Transition/
Not allocated
Evotec Group
External revenues 248,946 61,807 - 10,609 321,362
Intersegment revenues 59,126 - (59,126) - -
Gross margin in % 28.3 29.7 - - 30.7
R&D expenses (841) (47,093) 6,649 - (41,285)
SG&A expenses (35,889) (10,341) - - (46,230)
Impairment of intangible assets - (10,272) - - (10,272)
Impairment of intangible of goodwill - (1,647) - - (1,647)
Other operating income (expenses), net 14,562 32,488 - - 47,050
Operating result 64,964 (18,539) - - 46,425
Adjusted EBITDA1) 97,412 (4,196)     93,216

1)Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

First nine months 2018


  EVT Execute EVT Innovate Intersegment eliminations Transition/
Not allocated
Evotec Group1)
External revenues 218,745 51,272 - 8,071 278,088
Intersegment revenues 35,607 - (35,607) - -
Gross margin in % 24.6 48.8     30.1
R&D expenses (652) (24,122) 3,831 - (20,943)
SG&A expenses (34,478) (6,275) - - (40,753)
Impairment of intangible assets - (4,167) - - (4,167)
Income from bargain purchase - - - 15,400 15,400
Other operating income (expenses), net 13,009 13,280 - - 26,289
Operating result 40,386 3,732 - - 59,518
Adjusted EBITDA2) 62,143 6,574     68,717

1) Including reclasses of recharges according to IFRS 15
2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as
well as the total non-operating result

Key figures of consolidated interim statement of financial position
Evotec SE and subsidiaries


  30 September
31 December
in %
Cash, cash equivalents and investments 282,627 149,449 89.1
Net working capital 9,317 (39,036) >100.0
Current and non-current loan liabilities and lease obligations 438,538 114,465 >100.0
Total stockholders' equity 462,628 424,880 8.9
Total assets 1,083,921 771,883 40.4

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255,

12.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 909991

End of News DGAP News Service

Editor Details

Last Updated: 12-Nov-2019